NCT03692299View on ClinicalTrials.gov

Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 26, 2019

Study Completion Date

July 26, 2019

Conditions
Systemic SclerosisSmall Intestinal Bacterial Overgrowth
Interventions
DRUG

Saccharomyces Boulardii Oral Tablet

Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.

DRUG

Metronidazole

Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months

Trial Locations (1)

07800

Maria del Pilar Cruz Dominguez, Mexico City

All Listed Sponsors
lead

Coordinación de Investigación en Salud, Mexico

OTHER_GOV

NCT03692299 - Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis | Biotech Hunter | Biotech Hunter